Liraglutide

Since Liraglutide and Semiglutide have become “explosive”, the weight loss track has been regarded as the new blue ocean of biomedicine.

On June 13, Hong Kong-listed company China Biopharmaceutical (01177.HK) announced that it has reached a cooperation agreement with Hongyun Huining (Hangzhou) Biopharmaceutical Co., LTD., to jointly develop a dual-target anti-damage new drug GMA106, and Hongyun Huining will receive up to 57 million US dollars in down payment and milestone payment from the transaction; China Biopharmaceutical will get the exclusive development and commercialization rights of GMA106 in Greater China, which has officially entered the 100 billion weight reduction market.

It is understood that GMA106 is a GIPR (gastric inhibitory polypeptide receptor) antagonist /GLP-1R (glucagon-like peptide-1 receptor) activator, and M-Body technology can enable it to activate GLP-1R while specifically blocking GIPR signaling pathway, and achieve better weight loss effect than single GLP-1 receptor agonist through multi-pathway collaboration. The fat content per unit of body weight was reduced without reducing muscle mass.

M-bodies are a class of molecules specifically designed to interfere with more than one signaling pathway. This class of molecules usually consists of a core antibody and biologically active fragments. The M-Body antibody developed by this structural design has the advantages of stable structure, long lasting effect and easy production and purification.

In addition, the value of target GIPR is also focused on facilitating the generation of GLP1 agonists in the field of diabetes, while avoiding the side effects of GLP1 therapy with nausea and vomiting.

At present, the field of drugs targeting “GLP-1R” has appeared such “explosive” products as Liraglutide and Semaglutide. But the industry’s upgrade of “weight loss” related drugs continues: better drug effects are needed; And patient benefits, including fewer injections, fewer side effects, and progression from injection to oral. A typical example is the GLP-1/GIP dual-target drug Tirzepatide developed by Eli Lilly. On April 21 this year, the Phase III weight loss study of Telpotide has been launched, and is carrying out a “head-to-head study” with Novo Nord Semaglutide, competing for industry heights.

As a dual-target drug, GMA106 can also regulate both GIPR and GLP-1R signaling pathways, and has therapeutic effects on obesity, non-alcoholic fatty liver disease and diabetes. The latest Phase 1 data from AMG133, the Amgen pipeline that targets and acts the same way as GMA106, showed that obese patients treated with the drug reduced their body weight by 14.5% compared to baseline after 12 weeks of high-dose treatment, which is better than similar products.
In addition to weight loss and fat loss, GMA106 is also expected to mechanically address the cause of type 2 diabetes, namely insulin resistance, and further fill the unmet medical needs of type 2 diabetes patients worldwide. In addition, GMA106 is said to have potential for the treatment of Non-alcoholic steatohepatitis (NASH).